New Immune-Boosting combo targets Tough-to-Treat bone and soft tissue cancers
NCT ID NCT04668300
Summary
This study is testing whether two immunotherapy drugs, oleclumab and durvalumab, can help control advanced sarcomas that have come back, stopped responding to treatment, or spread. The drugs aim to help the patient's own immune system recognize and attack the cancer cells. The trial is for people aged 12 and older with specific types of sarcoma who have already tried standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.